Bharat Mocherla
Nuclear Imaging & Therapy · Las Vegas, NVNPI 1841451234
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 3 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 3 manufacturers reported payments, led by Biogen at 45.9% of the total.
Across 3 payments — averaging $46.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$63
- Eisai Inc.$51
- AbbVie$24
Across 284 payments — averaging $90,933 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$20.8M
- Biogen$4.4M
- Eisai Inc.$238K
- Cleerly, Inc.$121K
- Regeneron$100K
- Boehringer Ingelheim$43K
- plus $61K from 5 others
What the payments were for
- Food & beverage$138100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 1 | $63 |
| Eisai Inc. | 1 | $51 |
| AbbVie | 1 | $24 |
How this compares
Too few nuclear imaging & therapy providers in Nevadato place this figure against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.